ArticleClinical kidney journal2025
Allopurinol use predicts lower low-density lipoprotein cholesterol in patients with pre-dialysis chronic kidney disease-a prospective cohort study.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Uric Acid Extremes and Lipid Dysregulation: Evidence from a Large Population-Based Study.Metabolites · 2026Article
- Allopurinol and Alkaline Phosphatase Levels in Patients with Non-Dialysis CKD.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperuricemia influences lipid metabolism, yet relationships between urate-lowering therapy with allopurinol, serum urate, and lipid levels in patients with chronic kidney disease remain underexplored. Methods: This was a post-hoc analysis of 1970 participants of the CAN AIM to PREVENT who had pre-dialysis chronic kidney disease and were not receiving lipid-lowering therapy or febuxostat. Joint generalized structural equation modeling was used to investigate associations between allopurinol use (yes or no), serum urate [as a continuous or categorical variable (target if <6 mg/dl or high if ≥6 mg/dl)], and lipid levels [total cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein cholesterol, and triglycerides) assessed every 6 months for up to 3 years, along with time-to-event outcomes (death or initiation of renal replacement therapy), adjusting for demographic and clinical factors. Mediation analysis was used to determine allopurinol's direct and indirect effects (via urate) on lipid levels. Results: Allopurinol use independently predicted lower total cholesterol (-7.94%, 95% CI: -12.13% to -3.54%, Conclusion: Allopurinol use predicted lower total and especially LDL cholesterol independently of serum urate in this cohort of patients with pre-dialysis chronic kidney disease. Future studies could investigate underlying mechanisms, evaluate clinical implications, and confirm these findings in this and other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.